Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial
- DOI
- 10.1016/s1474-4422(26)00215-2
- Published
- 2026-08
- Container
- The Lancet Neurology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s1474-4422-26-00215-2,
title = {Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial},
author = {Hubert H Fernandez and Perminder Bhatia and Leslie Cloud and Urban M Fietzek and Michele Matarazzo and Eric Molho and Elizabeth Peckham and Arjun Tarakad and Cari Combs and Matthew Leoni and Ih Chang and Stacey Tringali and Joey Boiser and Raymond Sanchez and Cindy Zadikoff},
year = {2026},
journal = {The Lancet Neurology},
doi = {10.1016/s1474-4422(26)00215-2},
url = {https://doi.org/10.1016/s1474-4422(26)00215-2}
}RIS
TY - JOUR TI - Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial AU - Hubert H Fernandez AU - Perminder Bhatia AU - Leslie Cloud AU - Urban M Fietzek AU - Michele Matarazzo AU - Eric Molho AU - Elizabeth Peckham AU - Arjun Tarakad AU - Cari Combs AU - Matthew Leoni AU - Ih Chang AU - Stacey Tringali AU - Joey Boiser AU - Raymond Sanchez AU - Cindy Zadikoff PY - 2026 JO - The Lancet Neurology DO - 10.1016/s1474-4422(26)00215-2 UR - https://doi.org/10.1016/s1474-4422(26)00215-2 ER -
APA
Fernandez, H. H., Bhatia, P., Cloud, L., Fietzek, U. M., Matarazzo, M., Molho, E., Peckham, E., Tarakad, A., Combs, C., Leoni, M., Chang, I., Tringali, S., Boiser, J., Sanchez, R., & Zadikoff, C. (2026). Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(26)00215-2
Source records
- crossref · retrieved 2026-09-26T13:35:43.388Z